Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Annals of Hematology
Erschienen in: Annals of Hematology 5/2024

01.08.2023 | Review Article

Non-coding RNAs in leukemia drug resistance: new perspectives on molecular mechanisms and signaling pathways

verfasst von: Atefe Rahmati, Alireza Mafi, Omid Vakili, Firooze Soleymani, Zahra Alishahi, Sheida Yahyazadeh, Yasaman Gholinezhad, Malihe Rezaee, Thomas P. Johnston, Amirhossein Sahebkar

Erschienen in: Annals of Hematology | Ausgabe 5/2024

Einloggen, um Zugang zu erhalten

Abstract

Like almost all cancer types, timely diagnosis is needed for leukemias to be effectively cured. Drug efflux, attenuated drug uptake, altered drug metabolism, and epigenetic alterations are just several of the key mechanisms by which drug resistance develops. All of these mechanisms are orchestrated by up- and downregulators, in which non-coding RNAs (ncRNAs) do not encode specific proteins in most cases; albeit, some of them have been found to exhibit the potential for protein-coding. Notwithstanding, ncRNAs are chiefly known for their contribution to the regulation of physiological processes, as well as the pathological ones, such as cell proliferation, apoptosis, and immune responses. Specifically, in the case of leukemia chemo-resistance, ncRNAs have been recognized to be responsible for modulating the initiation and progression of drug resistance. Herein, we comprehensively reviewed the role of ncRNAs, specifically its effect on molecular mechanisms and signaling pathways, in the development of leukemia drug resistance.
Literatur
1.
Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG (2013) Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 13(10):714–726PubMedCrossRef
2.
Short NJ, Konopleva M, Kadia TM, Borthakur G, Ravandi F, DiNardo CD et al (2020) Advances in the treatment of acute myeloid leukemia: new drugs and new challenges advances in AML therapeutics. Cancer discovery 10(4):506–525PubMedCrossRef
3.
Crick FH (1958) On protein synthesis. Symp Soc Exp Biol 12:138–63PubMed
4.
Kimura T (2020) Non-coding natural antisense RNA: mechanisms of action in the regulation of target gene expression and its clinical implications. Yakugaku Zasshi 140(5):687–700PubMedCrossRef
5.
Wong CM, Tsang FH, Ng IO (2018) Non-coding RNAs in hepatocellular carcinoma: molecular functions and pathological implications. Nat Rev Gastroenterol Hepatol 15(3):137–151PubMedCrossRef
6.
Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE et al (2000) The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 403(6772):901–906PubMedCrossRef
7.
8.
Saw PE, Xu X, Chen J, Song EW (2021) Non-coding RNAs: the new central dogma of cancer biology. Sci China Life Sci 64(1):22–50PubMedCrossRef
9.
Zhang P, Wu W, Chen Q, Chen M (2019) Non-coding RNAs and their integrated networks. J Integr Bioinform 16(3):20190027
10.
Panni S, Lovering RC, Porras P, Orchard S (1863) Non-coding RNA regulatory networks. Biochim Biophys Acta Gene Regul Mech 2020(6):194417CrossRef
11.
12.
13.
14.
15.
Anastasiadou E, Jacob LS, Slack FJ (2018) Non-coding RNA networks in cancer. Nat Rev Cancer 18(1):5–18PubMedCrossRef
16.
E Nicolas F. Role of ncRNAs in development, diagnosis and treatment of human cancer. Recent Pat Anticancer Drug Discov 2017;12(2):128-135
17.
Salehi M, Vafadar A, Khatami SH, Taheri-Anganeh M, Vakili O, Savardashtaki A et al Gastrointestinal cancer drug resistance: the role of exosomal miRNAs. Mol Biol Rep 49(3):2421–2432
18.
Movahedpour A, Khatami SH, Khorsand M, Salehi M, Savardashtaki A, Mirmajidi SH et al (2021) Exosomal noncoding RNAs: key players in glioblastoma drug resistance. Mol Cell Biochem 476:4081–4092PubMedCrossRef
19.
20.
21.
22.
23.
24.
Dong H, Lei J, Ding L, Wen Y, Ju H, Zhang X (2013) MicroRNA: function, detection, and bioanalysis. Chem Rev 113(8):6207–6233PubMedCrossRef
25.
Bahmyari S, Jamali Z, Khatami SH, Vakili O, Roozitalab M, Savardashtaki A et al (2021) microRNAs in female infertility: an overview. Cell Biochem Funct 39(8):955–969PubMedCrossRef
26.
27.
Mafi A, Rahmati A, Babaei Aghdam Z, Salami R, Salami M, Vakili O et al (2022) Recent insights into the microRNA-dependent modulation of gliomas from pathogenesis to diagnosis and treatment. Cell Mol Biol Lett 27(1):1–32CrossRef
28.
Yi R, Qin Y, Macara IG, Cullen BR. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev 2003;17(24):3011-6
29.
Vishnoi A, Rani S (2017) MiRNA Biogenesis and regulation of diseases: an overview. Methods Mol Biol 1509:1–10PubMedCrossRef
30.
Pistritto G, Trisciuoglio D, Ceci C, Garufi A, D’Orazi G. Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies. Aging (Albany NY). 2016;8(4):603-619
31.
Azimi Sanavi M, Mahdavian F, Dorosti N, Karami N, Karami S, Khatami SH et al A review of highly sensitive electrochemical genosensors for microRNA detection: a novel diagnostic platform for neurodegenerative diseases diagnostics. Biotechnol Appl Biochem
32.
33.
34.
Babar IA, Cheng CJ, Booth CJ, Liang X, Weidhaas JB, Saltzman WM et al (2012) Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. Proc Natl Acad Sci U S A 109(26):E1695–E1704PubMedPubMedCentralCrossRef
35.
Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E et al (2002) Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 99(24):15524–15529PubMedPubMedCentralCrossRef
36.
Ghasabi M, Mansoori B, Mohammadi A, Duijf PH, Shomali N, Shirafkan N et al (2019) MicroRNAs in cancer drug resistance: basic evidence and clinical applications. J Cell Physiol 234(3):2152–2168PubMedCrossRef
37.
Giovannetti E, Erozenci A, Smit J, Danesi R, Peters GJ (2012) Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. Crit Rev Oncol Hematol 81(2):103–122PubMedCrossRef
38.
Liang YN, Tang YL, Ke ZY, Chen YQ, Luo XQ, Zhang H et al (2017) MiR-124 contributes to glucocorticoid resistance in acute lymphoblastic leukemia by promoting proliferation, inhibiting apoptosis and targeting the glucocorticoid receptor. J Steroid Biochem Mol Biol 172:62–68PubMedCrossRef
39.
Lau NC, Lim LP, Weinstein EG, Bartel DP (2001) An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science 294(5543):858–862PubMedCrossRef
40.
Brockdorff N, Ashworth A, Kay GF, McCabe VM, Norris DP, Cooper PJ et al (1992) The product of the mouse Xist gene is a 15 kb inactive X-specific transcript containing no conserved ORF and located in the nucleus. Cell 71(3):515–526PubMedCrossRef
41.
Guttman M, Donaghey J, Carey BW, Garber M, Grenier JK, Munson G et al (2011) lincRNAs act in the circuitry controlling pluripotency and differentiation. Nature 477(7364):295–300PubMedPubMedCentralCrossRef
42.
Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, Tilgner H et al (2012) The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res 22(9):1775–1789PubMedPubMedCentralCrossRef
43.
Zhang X, Hong R, Chen W, Xu M, Wang L (2019) The role of long noncoding RNA in major human disease. Bioorg Chem 92:103214PubMedCrossRef
44.
Statello L, Guo CJ, Chen LL, Huarte M (2021) Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol 22(2):96–118PubMedCrossRef
45.
Gourvest M, Brousset P, Bousquet M (2019) Long noncoding RNAs in acute myeloid leukemia: functional characterization and clinical relevance. Cancers (Basel) 11(11):1638
46.
Novikova IV, Hennelly SP, Tung CS, Sanbonmatsu KY (2013) Rise of the RNA machines: exploring the structure of long non-coding RNAs. J Mol Biol 425(19):3731–3746PubMedCrossRef
47.
Mercer TR, Mattick JS (2013) Structure and function of long noncoding RNAs in epigenetic regulation. Nat Struct Mol Biol 20(3):300–307PubMedCrossRef
48.
McCabe EM, Rasmussen TP (2021) lncRNA involvement in cancer stem cell function and epithelial-mesenchymal transitions. Semin Cancer Biol 75:38–48PubMedCrossRef
49.
Alessio E, Bonadio RS, Buson L, Chemello F, Cagnin S (2020) A single cell but many different transcripts: a journey into the world of long non-coding RNAs. Int J Mol Sci 21(1):302
50.
Luo H, Zhu G, Xu J, Lai Q, Yan B, Guo Y et al (2019) HOTTIP lncRNA promotes hematopoietic stem cell self-renewal leading to AML-like disease in mice. Cancer Cell 36(6):645–59.e8PubMedPubMedCentralCrossRef
51.
Li W, Zhai L, Wang H, Liu C, Zhang J, Chen W et al (2016) Downregulation of LncRNA GAS5 causes trastuzumab resistance in breast cancer. Oncotarget 7(19):27778–27786PubMedPubMedCentralCrossRef
52.
Zhang XW, Bu P, Liu L, Zhang XZ, Li J (2015) Overexpression of long non-coding RNA PVT1 in gastric cancer cells promotes the development of multidrug resistance. Biochem Biophys Res Commun 462(3):227–232PubMedCrossRef
53.
Movahedpour A, Vakili O, Khalifeh M, Mousavi P, Mahmoodzadeh A, Taheri-Anganeh M et al (2022) Mammalian target of rapamycin (mTOR) signaling pathway and traumatic brain injury: a novel insight into targeted therapy. Cell Biochem Funct 40(3):232–247PubMedCrossRef
54.
Yu Y, Kou D, Liu B, Huang Y, Li S, Qi Y et al (2020) LncRNA MEG3 contributes to drug resistance in acute myeloid leukemia by positively regulating ALG9 through sponging miR-155. Int J Lab Hematol 42(4):464–472PubMedCrossRef
55.
56.
Huang G, Li S, Yang N, Zou Y, Zheng D, Xiao T (2017) Recent progress in circular RNAs in human cancers. Cancer Lett 404:8–18PubMedCrossRef
57.
Salami R, Salami M, Mafi A, Vakili O, Asemi Z (2022) Circular RNAs and glioblastoma multiforme: focus on molecular mechanisms. Cell Commun Signal 20(1):13PubMedPubMedCentralCrossRef
58.
Zhang Y, Zhang XO, Chen T, Xiang JF, Yin QF, Xing YH et al (2013) Circular intronic long noncoding RNAs. Mol Cell 51(6):792–806PubMedCrossRef
59.
Mafi A, Yadegar N, Salami M, Salami R, Vakili O, Aghadavod E (2021) Circular RNAs; powerful microRNA sponges to overcome diabetic nephropathy. Pathol Res Pract 227:153618PubMedCrossRef
60.
Najafi S, Zarch SMA, Majidpoor J, Pordel S, Aghamiri S, Rasul MF et al (2022) Recent insights into the roles of circular RNAs in human brain development and neurologic diseases. Int J Biol Macromol 225:1038–1048PubMedCrossRef
61.
Li Z, Huang C, Bao C, Chen L, Lin M, Wang X et al (2015) Exon-intron circular RNAs regulate transcription in the nucleus. Nat Struct Mol Biol 22(3):256–264PubMedCrossRef
62.
63.
Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A et al (2013) Circular RNAs are a large class of animal RNAs with regulatory potency. Nature 495(7441):333–338PubMedCrossRef
64.
Vakili O, Asili P, Babaei Z, Mirahmad M, Keshavarzmotamed A, Asemi Z, et al (2022) Circular RNAs in Alzheimer’s disease: a new perspective of diagnostic and therapeutic targets. CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders). https://​doi.​org/​10.​2174/​1871527321666220​829164211
65.
Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK et al (2013) Natural RNA circles function as efficient microRNA sponges. Nature 495(7441):384–388PubMedCrossRef
66.
Ashwal-Fluss R, Meyer M, Pamudurti NR, Ivanov A, Bartok O, Hanan M et al (2014) circRNA biogenesis competes with pre-mRNA splicing. Mol Cell 56(1):55–66PubMedCrossRef
67.
Dorostgou Z, Yadegar N, Dorostgou Z, Khorvash F, Vakili O (2022) Novel insights into the role of circular RNAs in Parkinson disease: an emerging renaissance in the management of neurodegenerative diseases. J Neurosci Res 100(9):1775–1790PubMedCrossRef
68.
Kristensen LS, Hansen TB, Venø MT, Kjems J (2018) Circular RNAs in cancer: opportunities and challenges in the field. Oncogene 37(5):555–565PubMedCrossRef
69.
Croce CM (2016) Retraction: are circRNAs involved in cancer pathogenesis? Nat Rev Clin Oncol 13(11):658PubMed
70.
Liu J, Kong F, Lou S, Yang D, Gu L (2018) Global identification of circular RNAs in chronic myeloid leukemia reveals hsa_circ_0080145 regulates cell proliferation by sponging miR-29b. Biochem Biophys Res Commun 504(4):660–665PubMedCrossRef
71.
Xu T, Wang M, Jiang L, Ma L, Wan L, Chen Q et al (2020) CircRNAs in anticancer drug resistance: recent advances and future potential. Mol Cancer 19(1):127PubMedPubMedCentralCrossRef
72.
Cao HX, Miao CF, Sang LN, Huang YM, Zhang R, Sun L et al (2020) Circ_0009910 promotes imatinib resistance through ULK1-induced autophagy by sponging miR-34a-5p in chronic myeloid leukemia. Life Sci 243:117255PubMedCrossRef
73.
Liu Y, Dong Y, Zhao L, Su L, Luo J (2018) Circular RNA-MTO1 suppresses breast cancer cell viability and reverses monastrol resistance through regulating the TRAF4/Eg5 axis. Int J Oncol 53(4):1752–1762PubMed
74.
75.
Kurrey NK, Jalgaonkar SP, Joglekar AV, Ghanate AD, Chaskar PD, Doiphode RY et al (2009) Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells 27(9):2059–2068PubMedCrossRef
76.
Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M et al (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352(8):786–792PubMedCrossRef
77.
Ward RA, Fawell S, Floc'h N, Flemington V, McKerrecher D, Smith PD (2021) Challenges and opportunities in cancer drug resistance. Chem Rev 121(6):3297–3351PubMedCrossRef
78.
Moeinabadi-Bidgoli K, Rezaee M, Rismanchi H, Mohammadi MM, Babajani A (2022) Mesenchymal stem cell-derived antimicrobial peptides as potential anti-neoplastic agents: new insight into anticancer mechanisms of stem cells and exosomes. Front Cell Dev Biol 10:900418
79.
Farawela HM, Khorshied MM, Kassem NM, Kassem HA, Zawam HM (2014) The clinical relevance and prognostic significance of adenosine triphosphate ATP-binding cassette (ABCB5) and multidrug resistance (MDR1) genes expression in acute leukemia: an Egyptian study. J Cancer Res Clin Oncol 140(8):1323–1330PubMedCrossRef
80.
Ji Q, Qiu L (2016) Mechanism study of PEGylated polyester and β-cyclodextrin integrated micelles on drug resistance reversal in MRP1-overexpressed HL60/ADR cells. Colloids Surf B Biointerfaces 144:203–213PubMedCrossRef
81.
Hart SM, Ganeshaguru K, Scheper RJ, Prentice HG, Hoffbrand AV, Mehta AB (1997) Expression of the human major vault protein LRP in acute myeloid leukemia. Exp Hematol 25(12):1227–1232PubMed
82.
Shtil AA, Ktitorova OV, Kakpakova ES, Holian O (2000) Differential effects of the MDR1 (multidrug resistance) gene-activating agents on protein kinase C: evidence for redundancy of mechanisms of acquired MDR in leukemia cells. Leuk Lymphoma 40(1-2):191–195PubMedCrossRef
83.
Perl AE, Altman JK, Cortes J, Smith C, Litzow M, Baer MR et al (2017) Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. Lancet Oncol 18(8):1061–1075PubMedPubMedCentralCrossRef
84.
Stephen AG, Esposito D, Bagni RK, McCormick F (2014) Dragging ras back in the ring. Cancer Cell 25(3):272–281PubMedCrossRef
85.
Chen P, Huang H, Wu J, Lu R, Wu Y, Jiang X et al (2015) Bone marrow stromal cells protect acute myeloid leukemia cells from anti-CD44 therapy partly through regulating PI3K/Akt-p27(Kip1) axis. Mol Carcinog 54(12):1678–1685PubMedCrossRef
86.
Tazzari PL, Cappellini A, Ricci F, Evangelisti C, Papa V, Grafone T et al (2007) Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts. Leukemia 21(3):427–438PubMedCrossRef
87.
Liu X, Liao W, Peng H, Luo X, Luo Z, Jiang H et al (2016) miR-181a promotes G1/S transition and cell proliferation in pediatric acute myeloid leukemia by targeting ATM. J Cancer Res Clin Oncol 142(1):77–87PubMedCrossRef
88.
Tian P, Yan L (2016) Inhibition of microRNA-149-5p induces apoptosis of acute myeloid leukemia cell line THP-1 by targeting Fas ligand (FASLG). Med Sci Monit 22:5116–5123PubMedPubMedCentralCrossRef
89.
Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S et al (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2(5):561–566PubMedCrossRef
90.
Milojkovic D, Apperley J (2009) Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia. Clin Cancer Res 15(24):7519–7527PubMedCrossRef
91.
Eiring AM, Page BDG, Kraft IL, Mason CC, Vellore NA, Resetca D et al (2015) Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia. Leukemia 29(3):586–597PubMedCrossRef
92.
Ma L, Shan Y, Bai R, Xue L, Eide CA, Ou J et al (2014) A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia. Sci Transl Med 6(252):252ra121PubMedPubMedCentralCrossRef
93.
Holleman A, Cheok MH, den Boer ML, Yang W, Veerman AJ, Kazemier KM et al (2004) Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med 351(6):533–542PubMedCrossRef
94.
Bhojwani D, Kang H, Moskowitz NP, Min DJ, Lee H, Potter JW et al (2006) Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a children’s oncology group study. Blood 108(2):711–717PubMedPubMedCentralCrossRef
95.
Swerts K, De Moerloose B, Dhooge C, Laureys G, Benoit Y, Philippé J (2006) Prognostic significance of multidrug resistance-related proteins in childhood acute lymphoblastic leukaemia. Eur J Cancer 42(3):295–309PubMedCrossRef
96.
Pal Singh S, Dammeijer F, Hendriks RW (2018) Role of Bruton’s tyrosine kinase in B cells and malignancies. Mol Cancer 17(1):1–23CrossRef
97.
Liang C, Tian D, Ren X, Ding S, Jia M, Xin M et al (2018) The development of Bruton’s tyrosine kinase (BTK) inhibitors from 2012 to 2017: a mini-review. Eur J Med Chem 151:315–326PubMedCrossRef
98.
Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS et al (2014) Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib. N Engl J Med 370(24):2286–2294PubMedPubMedCentralCrossRef
99.
Chen B, Dragomir MP, Yang C, Li Q, Horst D, Calin GA (2022) Targeting non-coding RNAs to overcome cancer therapy resistance. Signal Transduct Target Ther 7(1):121PubMedPubMedCentralCrossRef
100.
Wang WT, Han C, Sun YM, Chen TQ, Chen YQ (2019) Noncoding RNAs in cancer therapy resistance and targeted drug development. J Hematol Oncol. 12(1):55PubMedPubMedCentralCrossRef
101.
Zebisch A, Hatzl S, Pichler M, Wölfler A, Sill H (2016) Therapeutic resistance in acute myeloid leukemia: the role of non-coding RNAs. Int J Mol Sci 17(12):2080PubMedPubMedCentralCrossRef
102.
Taghvimi S, Vakili O, Soltani Fard E, Khatami SH, Karami N, Taheri-Anganeh M et al (2022) Exosomal microRNAs and long noncoding RNAs: novel mediators of drug resistance in lung cancer. J Cell Physiol 237(4):2095–2106PubMedCrossRef
103.
Pavlíková L, Šereš M, Breier A, Sulová Z (2022) The roles of microRNAs in cancer multidrug resistance. Cancers (Basel) 14(4):1090
104.
105.
Sun YP, Lu F, Han XY, Ji M, Zhou Y, Zhang AM et al (2016) MiR-424 and miR-27a increase TRAIL sensitivity of acute myeloid leukemia by targeting PLAG1. Oncotarget 7(18):25276–25290PubMedPubMedCentralCrossRef
106.
Liu Y, Lei P, Qiao H, Sun K, Lu X, Bao F et al (2020) MicroRNA-33b regulates sensitivity to daunorubicin in acute myelocytic leukemia by regulating eukaryotic translation initiation factor 5A-2. J Cell Biochem 121(1):385–393PubMedCrossRef
107.
Liu Y, Lei P, Qiao H, Sun K, Lu X, Bao F et al (2019) miR-9 Enhances the chemosensitivity of AML cells to daunorubicin by targeting the EIF5A2/MCL-1 axis. Int J Biol Sci 15(3):579–586PubMedPubMedCentralCrossRef
108.
Vandewalle V, Essaghir A, Bollaert E, Lenglez S, Graux C, Schoemans H et al (2021) miR-15a-5p and miR-21-5p contribute to chemoresistance in cytogenetically normal acute myeloid leukaemia by targeting PDCD4, ARL2 and BTG2. J Cell Mol Med 25(1):575–585PubMedCrossRef
109.
Bai H, Xu R, Cao Z, Wei D, Wang C (2011) Involvement of miR-21 in resistance to daunorubicin by regulating PTEN expression in the leukaemia K562 cell line. FEBS Lett 585(2):402–408PubMedCrossRef
110.
Li Y, Zhu X, Gu J, Dong D, Yao J, Lin C et al (2010) Anti-miR-21 oligonucleotide sensitizes leukemic K562 cells to arsenic trioxide by inducing apoptosis. Cancer Sci 101(4):948–954PubMedCrossRef
111.
Bollaert E, Claus M, Vandewalle V, Lenglez S, Essaghir A, Demoulin J-B et al (2021) MiR-15a-5p confers chemoresistance in acute myeloid leukemia by inhibiting autophagy induced by daunorubicin. Int J Mol Sci 22(10):5153PubMedPubMedCentralCrossRef
112.
Wang Z, Fang Z, Lu R, Zhao H, Gong T, Liu D et al (2019) MicroRNA-204 potentiates the sensitivity of acute myeloid leukemia cells to arsenic trioxide. Oncol Res 27(9):1035PubMedPubMedCentralCrossRef
113.
Ganesan S, Palani HK, Lakshmanan V, Balasundaram N, Alex AA, David S et al (2019) Stromal cells downregulate miR-23a-5p to activate protective autophagy in acute myeloid leukemia. Cell Death Dis 10(10):1–14CrossRef
114.
Zhang Y, Liu Y, Xu X (2017) Upregulation of miR-142-3p improves drug sensitivity of acute myelogenous leukemia through reducing P-glycoprotein and repressing autophagy by targeting HMGB1. Transl Oncol 10(3):410–418PubMedPubMedCentralCrossRef
115.
Lu F, Zhang J, Ji M, Li P, Du Y, Wang H et al (2014) miR-181b increases drug sensitivity in acute myeloid leukemia via targeting HMGB1 and Mcl-1. Int J Oncol 45(1):383–392PubMedCrossRef
116.
Zhang Y, Chu X, Wei Q (2021) MiR-451 promotes cell apoptosis and inhibits autophagy in pediatric acute myeloid leukemia by targeting HMGB1. J Environ Pathol Toxicol Oncol 40(2):45–53PubMedCrossRef
117.
Dai C-W, Bai Q-W, Zhang G-S, Cao Y-X, Shen J-K, Pei M-F et al (2014) MicroRNA let-7f is down-regulated in patients with refractory acute myeloid leukemia and is involved in chemotherapy resistance of adriamycin-resistant leukemic cells. Leuk Lymphoma 55(7):1645–1648PubMedCrossRef
118.
Cao YX, Wen F, Luo ZY, Long XX, Luo C, Liao P et al (2020) Downregulation of microRNA let-7f mediated the adriamycin resistance in leukemia cell line. J Cell Biochem 121(10):4022–4033PubMedCrossRef
119.
Krakowsky RH, Wurm AA, Gerloff D, Katzerke C, Bräuer-Hartmann D, Hartmann J-U et al (2018) miR-451a abrogates treatment resistance in FLT3-ITD-positive acute myeloid leukemia. Blood Cancer J 8(3):1–4CrossRef
120.
Jia Y, Liu W, Zhan H-E, Yi X-P, Liang H, Zheng Q-L et al (2020) Roles of hsa-miR-12462 and SLC9A1 in acute myeloid leukemia. J Hematol Oncol 13(1):101PubMedPubMedCentralCrossRef
121.
Xiao Y, Deng T, Su C, Shang Z (2017) MicroRNA 217 inhibits cell proliferation and enhances chemosensitivity to doxorubicin in acute myeloid leukemia by targeting KRAS. Oncol Lett 13(6):4986–4994PubMedPubMedCentralCrossRef
122.
Liu H, Liu M, Zhang J, Liang Y (2020) Downregulated miR-130a enhances the sensitivity of acute myeloid leukemia cells to adriamycin. Mol Med Rep 22(4):2810–2816PubMedPubMedCentral
123.
Li X, Xu L, Sheng X, Cai J, Liu J, Yin T et al (2018) Upregulated microRNA-146a expression induced by granulocyte colony-stimulating factor enhanced low-dosage chemotherapy response in aged acute myeloid leukemia patients. Exp Hematol 68:66–79.e3PubMedCrossRef
124.
L-j T, G-k S, T-j Z, Wu D-h, J-d Z, Ma B-b et al (2019) Down-regulation of miR-29c is a prognostic biomarker in acute myeloid leukemia and can reduce the sensitivity of leukemic cells to decitabine. Cancer Cell Int 19(1):177CrossRef
125.
Wu YY, Lai HF, Huang TC, Chen YG, Ye RH, Chang PY et al (2021) Aberrantly reduced expression of miR-342-5p contributes to CCND1-associated chronic myeloid leukemia progression and imatinib resistance. Cell Death Dis 12(10):908PubMedPubMedCentralCrossRef
126.
Dong Y, Lin Y, Gao X, Zhao Y, Wan Z, Wang H et al (2019) Targeted blocking of miR328 lysosomal degradation with alkalized exosomes sensitizes the chronic leukemia cells to imatinib. Appl Microbiol Biotechnol 103(23-24):9569–9582PubMedCrossRef
127.
Jin J, Yao J, Yue F, Jin Z, Li D, Wang S (2018) Decreased expression of microRNA-214 contributes to imatinib mesylate resistance of chronic myeloid leukemia patients by upregulating ABCB1 gene expression. Exp Ther Med 16(3):1693–1700PubMedPubMedCentral
128.
Soltani I, Douzi K, Gharbi H, Benhassine I, Teber M, Amouri H et al (2017) Downregulation of miR-451 in Tunisian chronic myeloid leukemia patients: potential implication in imatinib resistance. Hematology 22(4):201–207PubMedCrossRef
129.
Li YL, Tang JM, Chen XY, Luo B, Liang GH, Qu Q et al (2020) MicroRNA-153-3p enhances the sensitivity of chronic myeloid leukemia cells to imatinib by inhibiting B-cell lymphoma-2-mediated autophagy. Hum Cell 33(3):610–618PubMedCrossRef
130.
Chen P-H, Liu A-J, Ho K-H, Chiu Y-T, Anne Lin Z-H, Lee Y-T et al (2018) microRNA-199a/b-5p enhance imatinib efficacy via repressing WNT2 signaling-mediated protective autophagy in imatinib-resistant chronic myeloid leukemia cells. Chem Biol Interact 291:144–151PubMedCrossRef
131.
Jiang X, Cheng Y, Hu C, Zhang A, Ren Y, Xu X (2019) MicroRNA-221 sensitizes chronic myeloid leukemia cells to imatinib by targeting STAT5. Leuk Lymphoma 60(7):1709–1720PubMedCrossRef
132.
Sun H, Li Y, Wang X, Zhou X, Rong S, Liang D et al (2022) TRIB2 regulates the expression of miR-33a-5p through the ERK/c-Fos pathway to affect the imatinib resistance of chronic myeloid leukemia cells. Int J Oncol 60(5):49PubMedPubMedCentralCrossRef
133.
Deng Y, Li X, Feng J, Zhang X (2018) Overexpression of miR-202 resensitizes imatinib resistant chronic myeloid leukemia cells through targetting Hexokinase 2. Biosci Rep 38(3):BSR20171383
134.
Farhadi E, Zaker F, Safa M, Rezvani MR (2016) miR-101 sensitizes K562 cell line to imatinib through Jak2 downregulation and inhibition of NF-κB target genes. Tumour Biol 37(10):14117–14128PubMedCrossRef
135.
Zhu X, Zhang J, Sun Y, Wang Y, Liu Q, Li P et al (2022) Restoration of miR-23a expression by chidamide sensitizes CML cells to imatinib treatment with concomitant downregulation of CRYAB. Bioengineered 13(4):8881–8892PubMedPubMedCentralCrossRef
136.
Ramachandran SS, Muiwo P, Ahmad HM, Pandey RM, Singh S, Bakhshi S et al (2017) miR-505-5p and miR-193b-3p: potential biomarkers of imatinib response in patients with chronic myeloid leukemia. Leuk Lymphoma 58(8):1981–1984PubMedCrossRef
137.
Lin H, Rothe K, Chen M, Wu A, Babaian A, Yen R et al (2020) The miR-185/PAK6 axis predicts therapy response and regulates survival of drug-resistant leukemic stem cells in CML. Blood 136(5):596–609PubMedPubMedCentralCrossRef
138.
Li Y, Luo S, Dong W, Song X, Zhou H, Zhao L et al (2016) Alpha-2, 3-sialyltransferases regulate the multidrug resistance of chronic myeloid leukemia through miR-4701-5p targeting ST3GAL1. Lab Invest 96(7):731–740PubMedCrossRef
139.
Zhou H, Li Y, Liu B, Shan Y, Li Y, Zhao L et al (2017) Downregulation of miR-224 and let-7i contribute to cell survival and chemoresistance in chronic myeloid leukemia cells by regulating ST3GAL IV expression. Gene 626:106–118PubMedCrossRef
140.
Ma J, Wu D, Yi J, Yi Y, Zhu X, Qiu H et al (2019) MiR-378 promoted cell proliferation and inhibited apoptosis by enhanced stem cell properties in chronic myeloid leukemia K562 cells. Biomed Pharmacother 112:108623PubMedCrossRef
141.
Nie ZY, Yao M, Yang Z, Yang L, Liu XJ, Yu J et al (2020) De-regulated STAT5A/miR-202-5p/USP15/Caspase-6 regulatory axis suppresses CML cell apoptosis and contributes to Imatinib resistance. J Exp Clin Cancer Res 39(1):17PubMedPubMedCentralCrossRef
142.
Min QH, Wang XZ, Zhang J, Chen QG, Li SQ, Liu XQ et al (2018) Exosomes derived from imatinib-resistant chronic myeloid leukemia cells mediate a horizontal transfer of drug-resistant trait by delivering miR-365. Exp Cell Res 362(2):386–393PubMedCrossRef
143.
Lv M, Zhang X, Jia H, Li D, Zhang B, Zhang H et al (2012) An oncogenic role of miR-142-3p in human T-cell acute lymphoblastic leukemia (T-ALL) by targeting glucocorticoid receptor-α and cAMP/PKA pathways. Leukemia 26(4):769–777PubMedCrossRef
144.
Piatopoulou D, Avgeris M, Marmarinos A, Xagorari M, Baka M, Doganis D et al (2017) miR-125b predicts childhood acute lymphoblastic leukaemia poor response to BFM chemotherapy treatment. Br J Cancer 117(6):801–812PubMedPubMedCentralCrossRef
145.
Sheybani Z, Rahgozar S, Ghodousi ES (2019) The Hedgehog signal transducer smoothened and microRNA-326: pathogenesis and regulation of drug resistance in pediatric B-cell acute lymphoblastic leukemia. Cancer Manag Res 11:7621–7630PubMedPubMedCentralCrossRef
146.
Zamani A, Fattahi Dolatabadi N, Houshmand M, Nabavizadeh N (2021) miR-324-3p and miR-508-5p expression levels could serve as potential diagnostic and multidrug-resistant biomarkers in childhood acute lymphoblastic leukemia. Leuk Res 109:106643PubMedCrossRef
147.
Qian L, Zhang W, Lei B, He A, Ye L, Li X et al (2016) MicroRNA-101 regulates T-cell acute lymphoblastic leukemia progression and chemotherapeutic sensitivity by targeting Notch1. Oncol Rep 36(5):2511–2516PubMedPubMedCentralCrossRef
148.
Saleh LM, Wang W, Herman SE, Saba NS, Anastas V, Barber E et al (2017) Ibrutinib downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemia. Leukemia 31(2):340–349PubMedCrossRef
149.
Zhu D-X, Zhu W, Fang C, Fan L, Zou Z-J, Wang Y-H et al (2012) miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes. Carcinogenesis 33(7):1294–1301PubMedCrossRef
150.
Pfeffer CM, Singh ATK (2018) Apoptosis: a target for anticancer therapy. Int J Mol Sci 19(2):448
151.
Ouyang L, Shi Z, Zhao S, Wang FT, Zhou TT, Liu B et al (2012) Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. Cell Prolif 45(6):487–498PubMedPubMedCentralCrossRef
152.
Ghavami S, Zamani M, Ahmadi M, Erfani M, Dastghaib S, Darbandi M et al (2022) Epigenetic regulation of autophagy in gastrointestinal cancers. Biochim Biophys Acta (BBA) - Mol Basis Dis 1868(11):166512
153.
Khan KH, Blanco-Codesido M, Molife LR (2014) Cancer therapeutics: targeting the apoptotic pathway. Crit Rev Oncol Hematol 90(3):200–219PubMedCrossRef
154.
Singh R, Letai A, Sarosiek K (2019) Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nat Rev Mol Cell Biol 20(3):175–193PubMedPubMedCentralCrossRef
155.
Wei Y, Cao Y, Sun R, Cheng L, Xiong X, Jin X et al (2020) Targeting Bcl-2 proteins in acute myeloid leukemia. Front Oncol 10:584974
156.
Trivedi R, Mishra DP (2015) Trailing TRAIL resistance: novel targets for TRAIL sensitization in cancer cells. Front Oncol 5:69
157.
158.
Daver N, Wei AH, Pollyea DA, Fathi AT, Vyas P, DiNardo CD (2020) New directions for emerging therapies in acute myeloid leukemia: the next chapter. Blood Cancer J 10(10):107PubMedPubMedCentralCrossRef
159.
Murphy T, Yee KWL (2017) Cytarabine and daunorubicin for the treatment of acute myeloid leukemia. Expert Opin Pharmacother 18(16):1765–1780PubMedCrossRef
160.
161.
Low CG, Luk IS, Lin D, Fazli L, Yang K, Xu Y et al (2013) BIRC6 protein, an inhibitor of apoptosis: role in survival of human prostate cancer cells. PLoS One 8(2):e55837PubMedPubMedCentralCrossRef
162.
163.
164.
Zheng Y, Ma L, Sun Q (2021) Clinically-relevant ABC transporter for anti-cancer drug resistance. Front Pharmacol 12:648407
165.
Wang F, Wang XS, Yang GH, Zhai PF, Xiao Z, Xia LY et al (2012) miR-29a and miR-142-3p downregulation and diagnostic implication in human acute myeloid leukemia. Mol Biol Rep 39(3):2713–2722PubMedCrossRef
166.
167.
Okabe S, Tauchi T, Katagiri S, Tanaka Y, Ohyashiki K (2014) Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells. J Hematol Oncol 7(1):37PubMedPubMedCentralCrossRef
168.
Poudel G, Tolland MG, Hughes TP, Pagani IS (2022) Mechanisms of resistance and implications for treatment strategies in chronic myeloid leukaemia. Cancers 14(14):3300PubMedPubMedCentralCrossRef
169.
Patel AB, O'Hare T, Deininger MW (2017) Mechanisms of resistance to ABL kinase inhibition in chronic myeloid leukemia and the development of next generation ABL kinase inhibitors. Hematol Oncol Clin North Am 31(4):589–612PubMedPubMedCentralCrossRef
170.
Bellodi C, Lidonnici MR, Hamilton A, Helgason GV, Soliera AR, Ronchetti M et al (2009) Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest 119(5):1109–1123PubMedPubMedCentralCrossRef
171.
Alves R, Gonçalves AC, Rutella S, Almeida AM, De Las RJ, Trougakos IP et al (2021) Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia-from molecular mechanisms to clinical relevance. Cancers (Basel) 13(19):4820
172.
Ye D, Wolff N, Li L, Zhang S, Ilaria RL Jr (2006) STAT5 signaling is required for the efficient induction and maintenance of CML in mice. Blood 107(12):4917–4925PubMedPubMedCentralCrossRef
173.
174.
175.
Ghodousi ES, Rahgozar S (2018) MicroRNA-326 and microRNA-200c: Two novel biomarkers for diagnosis and prognosis of pediatric acute lymphoblastic leukemia. J Cell Biochem 119(7):6024–6032PubMedCrossRef
176.
Zhang H, Sun Z, Liu Z, Song C (2018) Overcoming the emerging drug resistance of smoothened: an overview of small-molecule SMO antagonists with antiresistance activity. Future Med Chem 10(24):2855–2875PubMedCrossRef
177.
Wang A, Chen Y, Shi L, Li M, Li L, Wang S et al (2022) Tumor-suppressive MEG3 induces microRNA-493-5p expression to reduce arabinocytosine chemoresistance of acute myeloid leukemia cells by downregulating the METTL3/MYC axis. J Transl Med 20(1):288PubMedPubMedCentralCrossRef
178.
Yan J, Yao L, Li P, Wu G, Lv X (2022) Long non-coding RNA MIR17HG sponges microRNA-21 to upregulate PTEN and regulate homoharringtonine-based chemoresistance of acute myeloid leukemia cells. Oncol Lett 23(1):24PubMedCrossRef
179.
Dong X, Fang Z, Yu M, Zhang L, Xiao R, Li X et al (2018) Knockdown of long noncoding RNA HOXA-AS2 suppresses chemoresistance of acute myeloid leukemia via the miR-520c-3p/S100A4 Axis. Cell Physiol Biochem 51(2):886–896PubMedCrossRef
180.
Sun H, Sun Y, Chen Q, Xu Z (2020) LncRNA KCNQ1OT1 contributes to the progression and chemoresistance in acute myeloid leukemia by modulating Tspan3 through suppressing miR-193a-3p. Life Sci 241:117161PubMedCrossRef
181.
Kang Y, Zhang S, Cao W, Wan D, Sun L (2020) Knockdown of LncRNA CRNDE suppresses proliferation and P-glycoprotein-mediated multidrug resistance in acute myelocytic leukemia through the Wnt/β-catenin pathway. Biosci Rep 40:6CrossRef
182.
Chen L, Zhao H, Wang C, Hu N (2019) TUG1 knockdown enhances adriamycin cytotoxicity by inhibiting glycolysis in adriamycin-resistant acute myeloid leukemia HL60/ADR cells. RSC Adv. 9(19):10897–10904PubMedPubMedCentralCrossRef
183.
Zhang B, Sun YF, Zhang XM, Jiang N, Chen Q (2020) TUG1 weakens the sensitivity of acute myeloid leukemia cells to cytarabine by regulating miR-655-3p/CCND1 axis. Eur Rev Med Pharmacol Sci 24(9):4940–4953PubMed
184.
Li J, Wang M, Chen X (2020) Long non-coding RNA UCA1 modulates cell proliferation and apoptosis by regulating miR-296-3p/Myc axis in acute myeloid leukemia. Cell Cycle 19(12):1454–1465PubMedPubMedCentralCrossRef
185.
Chen L, Hu N, Wang C, Zhao H (2020) HOTAIRM1 knockdown enhances cytarabine-induced cytotoxicity by suppression of glycolysis through the Wnt/β-catenin/PFKP pathway in acute myeloid leukemia cells. Arch Biochem Biophys 680:108244PubMedCrossRef
186.
Liang L, Gu W, Li M, Gao R, Zhang X, Guo C et al (2021) The long noncoding RNA HOTAIRM1 controlled by AML1 enhances glucocorticoid resistance by activating RHOA/ROCK1 pathway through suppressing ARHGAP18. Cell Death Dis 12(7):702PubMedPubMedCentralCrossRef
187.
Liu JM, Li M, Luo W, Sun HB (2021) Curcumin attenuates adriamycin-resistance of acute myeloid leukemia by inhibiting the lncRNA HOTAIR/miR-20a-5p/WT1 axis. Lab Invest 101(10):1308–1317PubMedCrossRef
188.
Zhang H, Zhao Y, Liu X, Liu Y, Wang X, Fu Y et al (2021) A novel upregulated LncRNA-AC026150.8 promotes chemo-resistance and predicts poor prognosis in acute myeloid leukemia. Cancer Med 10(23):8614–8629PubMedPubMedCentralCrossRef
189.
Cui C, Wang Y, Gong W, He H, Zhang H, Shi W et al (2021) Long non-coding RNA LINC00152 regulates self-renewal of leukemia stem cells and induces chemo-resistance in acute myeloid leukemia. Front Oncol 11:694021PubMedPubMedCentralCrossRef
190.
Zhou H, Jia X, Yang F, Shi P (2021) Long noncoding RNA SATB1-AS1 contributes to the chemotherapy resistance through the microRNA-580/ 2′-5′-oligoadenylate synthetase 2 axis in acute myeloid leukemia. Bioengineered 12(1):6403–6417PubMedPubMedCentralCrossRef
191.
Zhang H, Liu L, Chen L, Liu H, Ren S, Tao Y (2021) Long noncoding RNA DANCR confers cytarabine resistance in acute myeloid leukemia by activating autophagy via the miR-874-3P/ATG16L1 axis. Mol Oncol 15(4):1203–1216PubMedPubMedCentralCrossRef
192.
Yang Y, Dai W, Sun Y, Zhao Z (2019) Long non-coding RNA linc00239 promotes malignant behaviors and chemoresistance against doxorubicin partially via activation of the PI3K/Akt/mTOR pathway in acute myeloid leukaemia cells. Oncol Rep 41(4):2311–2320PubMed
193.
Wang C, Li L, Li M, Wang W, Liu Y, Wang S (2020) Silencing long non-coding RNA XIST suppresses drug resistance in acute myeloid leukemia through down-regulation of MYC by elevating microRNA-29a expression. Mol Med 26(1):114PubMedPubMedCentralCrossRef
194.
Hu N, Chen L, Wang C, Zhao H (2019) MALAT1 knockdown inhibits proliferation and enhances cytarabine chemosensitivity by upregulating miR-96 in acute myeloid leukemia cells. Biomed Pharmacother 112:108720PubMedCrossRef
195.
Xue L, Li C, Ren J, Wang Y (2021) KDM4C contributes to cytarabine resistance in acute myeloid leukemia via regulating the miR-328-3p/CCND2 axis through MALAT1. Ther Adv Chronic Dis 12:2040622321997259PubMedPubMedCentralCrossRef
196.
Li Q, Wang J (2019) Long noncoding RNA ZFAS1 enhances adriamycin resistance in pediatric acute myeloid leukemia through the miR-195/Myb axis. RSC Adv 9(48):28126–28134PubMedPubMedCentralCrossRef
197.
Wang D, Zeng T, Lin Z, Yan L, Wang F, Tang L et al (2020) Long non-coding RNA SNHG5 regulates chemotherapy resistance through the miR-32/DNAJB9 axis in acute myeloid leukemia. Biomed Pharmacother 123:109802PubMedCrossRef
198.
Luo J, Gao Y, Lin X, Guan X (2021) Systematic analysis reveals a lncRNA-miRNA-mRNA network associated with dasatinib resistance in chronic myeloid leukemia. Ann Palliat Med 10(2):1727–1738PubMedCrossRef
199.
Wen F, Cao YX, Luo ZY, Liao P, Lu ZW (2018) LncRNA MALAT1 promotes cell proliferation and imatinib resistance by sponging miR-328 in chronic myelogenous leukemia. Biochem Biophys Res Commun 507(1-4):1–8PubMedCrossRef
200.
Han Y, Ma Z (2021) LncRNA highly upregulated in liver cancer regulates imatinib resistance in chronic myeloid leukemia via the miR-150-5p/MCL1 axis. Anticancer Drugs 32(4):427–436PubMedCrossRef
201.
Shehata AMF, Gohar SF, Muharram NM, Eldin SMK (2022) LncRNA CCAT2 expression at diagnosis predicts imatinib response in chronic phase chronic myeloid leukemia patients. Leuk Res 116:106838PubMedCrossRef
202.
Liu J, Yang L, Liu X, Liu L, Liu M, Feng X et al (2022) lncRNA HOTTIP Recruits EZH2 to inhibit PTEN expression and participates in IM resistance in chronic myeloid leukemia. Stem Cells Int 2022:9993393PubMedPubMedCentralCrossRef
203.
Dai H, Wang J, Huang Z, Zhang H, Wang X, Li Q et al (2021) LncRNA OIP5-AS1 promotes the autophagy-related imatinib resistance in chronic myeloid leukemia cells by regulating miR-30e-5p/ATG12 Axis. Technol Cancer Res Treat 20:15330338211052150PubMedPubMedCentralCrossRef
204.
Liu Y, Li H, Zhao Y, Li D, Zhang Q, Fu J et al (2022) Knockdown of ADORA2A antisense RNA 1 inhibits cell proliferation and enhances imatinib sensitivity in chronic myeloid leukemia. Bioengineered 13(2):2296–2307PubMedPubMedCentralCrossRef
205.
Xiao Y, Jiao C, Lin Y, Chen M, Zhang J, Wang J et al (2017) lncRNA UCA1 contributes to imatinib resistance by acting as a ceRNA against miR-16 in chronic myeloid leukemia cells. DNA Cell Biol 36(1):18–25PubMedCrossRef
206.
He B, Bai Y, Kang W, Zhang X, Jiang X (2017) LncRNA SNHG5 regulates imatinib resistance in chronic myeloid leukemia via acting as a CeRNA against MiR-205-5p. Am J Cancer Res 7(8):1704–1713PubMedPubMedCentral
207.
Zhou X, Yuan P, Liu Q, Liu Z (2017) LncRNA MEG3 regulates imatinib resistance in chronic myeloid leukemia via suppressing microRNA-21. Biomol Ther (Seoul) 25(5):490–496PubMedCrossRef
208.
Zhang F, Ni H, Li X, Liu H, Xi T, Zheng L (2019) LncRNA FENDRR attenuates adriamycin resistance via suppressing MDR1 expression through sponging HuR and miR-184 in chronic myelogenous leukaemia cells. FEBS Lett 593(15):1993–2007PubMedCrossRef
209.
Ouimet M, Drouin S, Lajoie M, Caron M, St-Onge P, Gioia R et al (2016) A childhood acute lymphoblastic leukemia-specific lncRNA implicated in prednisolone resistance, cell proliferation, and migration. Oncotarget 8(5):7477–7488PubMedCentralCrossRef
210.
Zhao Q, Zhao S, Li J, Zhang H, Qian C, Wang H et al (2019) TCF7L2 activated HOXA-AS2 decreased the glucocorticoid sensitivity in acute lymphoblastic leukemia through regulating HOXA3/EGFR/Ras/Raf/MEK/ERK pathway. Biomed Pharmacother 109:1640–1649PubMedCrossRef
211.
Miller CR, Ruppert AS, Fobare S, Chen TL, Liu C, Lehman A et al (2017) The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia. Oncotarget 8(16):25942–25954PubMedPubMedCentralCrossRef
212.
Martelli AM, Nyåkern M, Tabellini G, Bortul R, Tazzari PL, Evangelisti C et al (2006) Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. Leukemia 20(6):911–928PubMedCrossRef
213.
Li S, Yao W, Liu R, Gao L, Lu Y, Zhang H et al (2022) Long non-coding RNA LINC00152 in cancer: roles, mechanisms, and chemotherapy and radiotherapy resistance. Front Oncol 12:960193PubMedPubMedCentralCrossRef
214.
Ding J, Zhang X, Xue J, Fang L, Ban C, Song B et al (2021) CircNPM1 strengthens adriamycin resistance in acute myeloid leukemia by mediating the miR-345-5p/FZD5 pathway. Cent Eur J Immunol 46(2):162–182PubMedPubMedCentralCrossRef
215.
Shang J, Chen WM, Wang ZH, Wei TN, Chen ZZ, Wu WB (2019) CircPAN3 mediates drug resistance in acute myeloid leukemia through the miR-153-5p/miR-183-5p-XIAP axis. Exp Hematol 70:42–54.e3PubMedCrossRef
216.
Shang J, Chen WM, Liu S, Wang ZH, Wei TN, Chen ZZ et al (2019) CircPAN3 contributes to drug resistance in acute myeloid leukemia through regulation of autophagy. Leuk Res 85:106198PubMedCrossRef
217.
Wang J, Liang Y, Qin Y, Jiang G, Peng Y, Feng W (2022) circCRKL, a circRNA derived from CRKL, regulates BCR-ABL via sponging miR-877-5p to promote chronic myeloid leukemia cell proliferation. J Transl Med 20(1):395PubMedPubMedCentralCrossRef
218.
Lu YH, Huang ZY (2021) Global identification of circular RNAs in imatinib (IM) resistance of chronic myeloid leukemia (CML) by modulating signaling pathways of circ_0080145/miR-203/ABL1 and circ 0051886/miR-637/ABL1. Mol Med 27(1):148PubMedPubMedCentralCrossRef
219.
Zhong AN, Yin Y, Tang BJ, Chen L, Shen HW, Tan ZP et al (2021) CircRNA microarray profiling reveals hsa_circ_0058493 as a novel biomarker for imatinib-resistant CML. Front Pharmacol 12:728916PubMedPubMedCentralCrossRef
220.
221.
222.
223.
Naidu S, Magee P, Garofalo M (2015) MiRNA-based therapeutic intervention of cancer. J Hematol Oncol 8:1–8CrossRef
224.
Rabaan AA, AlSaihati H, Bukhamsin R, Bakhrebah MA, Nassar MS, Alsaleh AA et al (2023) Application of CRISPR/Cas9 technology in cancer treatment: a future direction. Curr Oncol 30(2):1954–1976PubMedPubMedCentralCrossRef
225.
Zhang H, Qin C, An C, Zheng X, Wen S, Chen W et al (2021) Application of the CRISPR/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer. Mol Cancer 20:1–22CrossRef
226.
Chen M, Mao A, Xu M, Weng Q, Mao J, Ji J (2019) CRISPR-Cas9 for cancer therapy: Opportunities and challenges. Cancer Lett 447:48–55PubMedCrossRef
227.
Khan MI, Hossain MI, Hossain MK, Rubel M, Hossain K, Mahfuz A et al (2022) Recent progress in nanostructured smart drug delivery systems for cancer therapy: a review. ACS Appl Bio Mater 5(3):971–1012PubMedCrossRef
Metadaten
Titel
Non-coding RNAs in leukemia drug resistance: new perspectives on molecular mechanisms and signaling pathways
verfasst von
Atefe Rahmati
Alireza Mafi
Omid Vakili
Firooze Soleymani
Zahra Alishahi
Sheida Yahyazadeh
Yasaman Gholinezhad
Malihe Rezaee
Thomas P. Johnston
Amirhossein Sahebkar
Publikationsdatum
01.08.2023
Verlag
Springer Berlin Heidelberg
Erschienen in
Annals of Hematology / Ausgabe 5/2024
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-023-05383-3

Weitere Artikel der Ausgabe 5/2024

Annals of Hematology 5/2024 Zur Ausgabe

Correspondence

Concomitant large deletion and de novo duplication of factor VIII gene in an Indian patient with severe Hemophilia A

Case Report

Gilteritinib combined with venetoclax and azacitidine for relapsed acute myeloid leukemia cocurrent with pure red cell aplasia after allogeneic hematopoietic stem cell transplantation: a case report

Case Report

Adult type I Gaucher disease with splenectomy caused by a compound heterozygous GBA1 mutation in a Chinese patient: a case report

Original Article

Diagnostic management of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in close interaction with therapeutic considerations

Editorial

Is eryptosis druggable?

Original Article

Spanish registry of hemoglobinopathies and rare anemias (REHem-AR): demographics, complications, and management of patients with β-thalassemia

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Hereditäres Angioödem: Tablette könnte Akuttherapie erleichtern

05.06.2024 Hereditäres Angioödem Nachrichten

Medikamente zur Bedarfstherapie bei hereditärem Angioödem sind bisher nur als Injektionen und Infusionen verfügbar. Der Arzneistoff Sebetralstat kann oral verabreicht werden und liefert vielversprechende Daten.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise